Luca Agnelli

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.⚑
  2016 L1 36/100 ⚑

1 assessed by us (0 reproduced) · 368 not yet assessed — every PubMed paper on record, linked below.

• A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers ↗

  ESMO Open · 2026 · PMID 41547215
  not yet assessed
• APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer ↗

  npj Precision Oncology · 2026 · PMID 41611893
  not yet assessed
• Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients ↗

  Tumori Journal · 2026 · PMID 42338283
  not yet assessed
• I3LUNG: Clinical Validation of a Multimodal AI Tool to Support Immunotherapy Decisions in NSCLC ↗

  medRxiv · 2026
  not yet assessed
• Editorial Expression of Concern: Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers ↗

  Nature Medicine · 2026 · PMID 41741727
  not yet assessed
• Transcriptomic Analysis of Children/Adolescents and Young Adults Versus Adult Synovial Sarcomas Reveals Age‐Related Molecular Features ↗

  Pediatric Blood & Cancer · 2026 · PMID 41852293
  not yet assessed
• 1041 Real World Molecular Profiling in High-Grade Serous Ovarian Carcinoma: NGS for Homologous Recombination Deficiency Characterization ↗

  Laboratory Investigation · 2026
  not yet assessed
• Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma ↗

  Journal of Cellular and Molecular Medicine · 2026 · PMID 41928426
  not yet assessed
• Abstract CT246: An ensemble multi-omics framework for chemo de-escaltion NSCLC patients with PD-L1-low/negative disease in the PEOPLE phase II trial (NCT03447678) ↗

  Cancer Research · 2026
  not yet assessed
• Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Journal of Experimental & Clinical Cancer Research · 2026 · PMID 42129855
  not yet assessed
• Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center ↗

  Endocrine · 2026 · PMID 42334691
  not yet assessed
• Additional file 3 of Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• Additional file 1 of Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• Additional file 2 of Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• Additional file 1 of Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• Additional file 2 of Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• Additional file 3 of Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling ↗

  Figshare · 2026
  not yet assessed
• PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression ↗

  Cancer Gene Therapy · 2026 · PMID 42432217
  not yet assessed
• The Non-Coding RNA Journal Club: Highlights on Recent Papers—15 ↗

  Non-Coding RNA · 2026 · PMID 42496242
  not yet assessed
• Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study ↗

  BMJ Open · 2025 · PMID 40379307
  not yet assessed
• Real-World Outcomes of Molecular Tumor Board Treatment Recommendations ↗

  JCO Precision Oncology · 2025 · PMID 40499091
  not yet assessed
• Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer ↗

  Frontiers in Oncology · 2025 · PMID 40842600
  not yet assessed
• Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study ↗

  ESMO Open · 2025 · PMID 41167086
  not yet assessed
• Detecting gene copy number alterations by Oncomine Comprehensive genomic profiling in a comparative study on FFPE tumor samples ↗

  Scientific Reports · 2025 · PMID 39910096
  not yet assessed
• Unveiling the Prognostic Role of Synaptophysin in Conventional Colorectal Carcinomas ↗

  Neuroendocrinology · 2025 · PMID 40324347
  not yet assessed
• Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials ↗

  npj Precision Oncology · 2025 · PMID 41398053
  not yet assessed
• Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization ↗

  Tumori Journal · 2025 · PMID 40629669
  not yet assessed
• Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy ↗

  Clinical Lung Cancer · 2025 · PMID 40976722
  not yet assessed
• Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer ↗

  JCO Precision Oncology · 2025 · PMID 41004702
  not yet assessed
• Nectin-4 and Trop-2 expression as potential therapeutic target in collecting duct carcinoma: Preliminary results from the CICERONE trial (NCT05372302). ↗

  Journal of Clinical Oncology · 2025
  not yet assessed
• Genomic Profiling of Mucosal Melanoma Identifies Novel Fusion Transcripts and Therapeutic Molecular Hubs ↗

  SSRN Electronic Journal · 2025
  not yet assessed
• Liquid Biopsies to Monitor Braf V600e-Mutant Anaplastic Thyroid Carcinoma: A Real-World Study in a Tertiary Cancer Center ↗

  SSRN Electronic Journal · 2025
  not yet assessed
• 1724 Unrevealing Spatial Differences in a Cohort of Highly Proliferative Lung Carcinoids with the GeoMx® Digital Spatial Profiler ↗

  Laboratory Investigation · 2025
  not yet assessed
• 21P Multi-omic characterization of CDK4/6 inhibitor resistance: The UNDERSTAND study ↗

  ESMO Open · 2025
  not yet assessed
• Abstract PS13-05: The UNDERSTAND trial: a multi-omic platform for investigating CDK4/6 inhibitors resistance mechanisms in HR+ advanced breast cancer ↗

  Clinical Cancer Research · 2025
  not yet assessed
• 2641P Systemic immunosuppressive and pro-inflammatory milieu associates with poor prognosis and resistance to therapy in metastatic Collecting Duct (CDC) carcinoma patients ↗

  Annals of Oncology · 2025
  not yet assessed
• UpSMART: five years of digital innovation in cancer clinical research—achievements, challenges, and recommendations ↗

  Frontiers in Digital Health · 2025 · PMID 41395630
  not yet assessed
• 15P An ensemble multi-omics framework to select NSCLC patients for chemo-de-escalation, PEOPLE phase II trial ↗

  ESMO Real World Data and Digital Oncology · 2025
  not yet assessed
• Altered osteoblast populations dynamics underlie myeloma progression from precursors diseases in bone microenvironment ↗

  Blood · 2025
  not yet assessed
• Metabolic profiling of therapy-induced senescent cancer cells via TPEF, MALDI-MS, and RNA-sequencing ↗

  Scientific Reports · 2025 · PMID 41408108
  not yet assessed
• Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO ↗

  Annals of Oncology · 2024 · PMID 39637944
  not yet assessed
• Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients ↗

  Cell Metabolism · 2024 · PMID 39694040
  not yet assessed
• Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma ↗

  Blood Advances · 2024 · PMID 38359407
  not yet assessed
• The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage ↗

  Non-Coding RNA · 2024 · PMID 39728607
  not yet assessed
• Molecular Characterization and Clinical Relevance of <i>MGMT</i>‐Silenced Pancreatic Cancer ↗

  Cancer Medicine · 2024 · PMID 39618336
  not yet assessed
• PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials ↗

  Tumori Journal · 2024 · PMID 38676437
  not yet assessed
• Is tumour sequencing effective for the identification of germline <i>BRCA1/2</i> pathogenic variant carriers? ↗

  Tumori Journal · 2024 · PMID 39311051
  not yet assessed
• Supplementary Figure S3 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Data from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Figure S3 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Figure S1 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Table S2 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Data from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Table S1 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Figure S2 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Figure S4 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Figure S1 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Table S2 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Table S1 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Figure S4 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Supplementary Figure S2 from Negative Hyperselection of Patients with HER2&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;RAS&lt;/i&gt; Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  2024
  not yet assessed
• Abstract 6848: Analysis of the bone microenvironment cells by single cell transcriptomics reveals altered features in multiple myeloma patients compared to pre-malignant monoclonal gammopathies ↗

  Cancer Research · 2024
  not yet assessed
• 85P Real-world molecular profiling in gynaecologic oncology: Shaping tailored treatments and leveraging genetic insights to provide personalized care ↗

  ESMO Open · 2024
  not yet assessed
• P-269 Pygo2 Is Overexpressed in Myeloma Cells With 1q21 Amplification Being Involved in Carfilzomib Resistance ↗

  Clinical Lymphoma Myeloma & Leukemia · 2024
  not yet assessed
• 143P A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers ↗

  ESMO Open · 2024
  not yet assessed
• Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients ↗

  Blood · 2024
  not yet assessed
• Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care ↗

  JCO Precision Oncology · 2023 · PMID 37487147
  not yet assessed
• PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 &lt;50%: a multiomics analysis ↗

  Journal for ImmunoTherapy of Cancer · 2023 · PMID 37286305
  not yet assessed
• Negative Hyperselection of Patients with HER2+ and <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ↗

  Clinical Cancer Research · 2023 · PMID 37610454
  not yet assessed
• APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research ↗

  Clinical Lung Cancer · 2023 · PMID 38262770
  not yet assessed
• Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice ↗

  Cancer Biomarkers · 2023 · PMID 37545217
  not yet assessed
• Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project ↗

  BMC Cancer · 2023 · PMID 37648965
  not yet assessed
• Identification of &lt;i&gt;PSMB4&lt;/i&gt; and &lt;i&gt;PSMD4&lt;/i&gt; as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma ↗

  Haematologica · 2023 · PMID 37608776
  not yet assessed
• ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC) ↗

  PLoS Genetics · 2023 · PMID 36595552
  not yet assessed
• A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei ↗

  Biomedicines · 2023 · PMID 37509688
  not yet assessed
• Prevalence of BRCA homopolymeric indels in an ION Torrent-based tumour-to-germline testing workflow in high-grade ovarian carcinoma ↗

  Scientific Reports · 2023 · PMID 37179432
  not yet assessed
• 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib ↗

  Annals of Oncology · 2023
  not yet assessed
• Evaluation of clinical benefit and progression-free survival ratio of targeted treatments in a prospective cohort study of patients with biliary tract cancers. ↗

  Journal of Clinical Oncology · 2023
  not yet assessed
• PYGO2-MDR1 Axis in Multiple Myeloma Patients with 1q21 Amplification As Promising Target to Overcome Carfilzomib Resistance ↗

  Blood · 2023
  not yet assessed
• A Novel Model Combining Circulating Absolute Monocyte Counts and a Four-Gene Monocyte Signature in Leukapheresis Identifies Lymphoma Patients at Very High Risk of Progression after Tisagenlecleucel or Axicabtagene Ciloleucel Therapy ↗

  Blood · 2023
  not yet assessed
• Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Table 1 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-2 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Table 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Table 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Table 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 1 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 1 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure 2 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• CCR Translation for This Article from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 5 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 4 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Table 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Supplementary Table 2 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Tables 1 - 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figures 1 - 6 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• Supplementary Table 2 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• Supplementary Table 1 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion ↗

  2023
  not yet assessed
• Data from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Data from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Data from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• Data from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Data from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Data from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Data from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Data from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  2023
  not yet assessed
• Data from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• Data from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Data from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Data from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure 5 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure 3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion ↗

  2023
  not yet assessed
• Supplementary Figure 1 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 1 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 2 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure 2 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 5 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 4 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Table 3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure 3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• CCR Translation for This Article from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Tables 1 - 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Figure 5 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  2023
  not yet assessed
• Supplementary Table 1 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• Supplementary Figures 1 - 6 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• Supplementary Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Table 1 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-2 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Table 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  2023
  not yet assessed
• Supplementary Table 2 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  2023
  not yet assessed
• P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA ↗

  HemaSphere · 2023
  not yet assessed
• P-180 PYGO2 is upregulated in multiple myeloma patients with 1q21+: a potential novel therapeutic target ↗

  Clinical Lymphoma Myeloma & Leukemia · 2023
  not yet assessed
• 2221P Precision oncology in advanced thyroid carcinomas: Impact of molecular tests on patients’ outcomes ↗

  Annals of Oncology · 2023
  not yet assessed
• Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples ↗

  Exploration of Targeted Anti-tumor Therapy · 2022 · PMID 36338518
  not yet assessed
• Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements ↗

  Frontiers in Oncology · 2022 · PMID 35837088
  not yet assessed
• <scp>MGMT</scp> inactivation as a new biomarker in patients with advanced biliary tract cancers ↗

  Molecular Oncology · 2022 · PMID 35621918
  not yet assessed
• Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma ↗

  Cancer Cell International · 2022 · PMID 36503426
  not yet assessed
• Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model ↗

  Frontiers in Oncology · 2022 · PMID 35463374
  not yet assessed
• The UpSMART Accelerator: driving digital innovation to change the conduct of early phase cancer medicine trials ↗

  Digital Medicine · 2022
  not yet assessed
• Molecular analyses of metastatic collecting ducts renal cell carcinoma from the phase 2 prospective trial of cabozantinib as first-line treatment (BONSAI trial Meeturo 2). ↗

  Journal of Clinical Oncology · 2022
  not yet assessed
• PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 &lt; 50%: A multiomics approach. ↗

  Journal of Clinical Oncology · 2022
  not yet assessed
• 1470P Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2) ↗

  Annals of Oncology · 2022
  not yet assessed
• Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification ↗

  Blood · 2022
  not yet assessed
• A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with <i>in-Vivo</i> CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy ↗

  Blood · 2022
  not yet assessed
• Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients ↗

  Cell Reports · 2021 · PMID 33730576
  not yet assessed
• Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells ↗

  Journal for ImmunoTherapy of Cancer · 2021 · PMID 34127544
  not yet assessed
• Bioinformatics Pipeline to Analyze lncRNA Arrays ↗

  Methods in molecular biology · 2021 · PMID 34160798
  not yet assessed
• Bioinformatic Pipelines to Analyze lncRNAs RNAseq Data ↗

  Methods in molecular biology · 2021 · PMID 34160799
  not yet assessed
• Editorial: Genomics of Lymphoproliferative Disease ↗

  Frontiers in Oncology · 2021 · PMID 33816317
  not yet assessed
• 319 Gynecologic malignancies in the era of precision medicine ↗

  International Journal of Gynecological Cancer · 2021
  not yet assessed
• PSMB4 and PSMD4 Are Correlated with 1q21 Amplification in CD138 + Plasma Cells: New Potential Druggable Targets in Myeloma Patients ↗

  Blood · 2021
  not yet assessed
• Revealing the Impact of Structural Variants in Multiple Myeloma ↗

  Blood Cancer Discovery · 2020 · PMID 33392515
  not yet assessed
• Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability ↗

  Cancers · 2020 · PMID 33167336
  not yet assessed
• Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach ↗

  Molecular Medicine · 2020 · PMID 32156260
  not yet assessed
• NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome ↗

  Non-Coding RNA · 2020 · PMID 32182990
  not yet assessed
• Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma ↗

  Cancers · 2020 · PMID 32218309
  not yet assessed
• Additional file 2 of Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach ↗

  Open MIND · 2020
  not yet assessed
• Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma ↗

  Leukemia · 2019 · PMID 31427718
  not yet assessed
• The transcriptomic profile of CD138⁺ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged ↗

  Haematologica · 2019 · PMID 30846495
  not yet assessed
• Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma ↗

  American Journal of Hematology · 2019 · PMID 30829413
  not yet assessed
• Targeted resequencing of FECH locus reveals that a novel deep intronic pathogenic variant and eQTLs may cause erythropoietic protoporphyria (EPP) through a methylation-dependent mechanism ↗

  Genetics in Medicine · 2019 · PMID 31273344
  not yet assessed
• The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs ↗

  Haematologica · 2019 · PMID 33054082
  not yet assessed
• Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing ↗

  Blood Cancer Journal · 2019 · PMID 30783080
  not yet assessed
• PS1360 LONG NON‐CODING RNA NEAT1 TARGETING TRIGGERS ANTI‐TUMOR ACTIVITY AND RESULTS IN CHEMO‐SENSITIZING EFFECT IN MULTIPLE MYELOMA CELLS ↗

  HemaSphere · 2019
  not yet assessed
• Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity ↗

  Leukemia · 2018 · PMID 29487387
  not yet assessed
• A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma ↗

  Scientific Reports · 2018 · PMID 29700321
  not yet assessed
• Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma ↗

  Haematologica · 2018 · PMID 30213829
  not yet assessed
• Long Non-Coding RNAs in Multiple Myeloma ↗

  Genes · 2018 · PMID 29389884
  not yet assessed
• Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma ↗

  Oncotarget · 2018 · PMID 29552331
  not yet assessed
• Abstract 4071: Investigation of thyroid tumor microenvironment by immunohistochemical and bioinformatic analyses ↗

  Cancer Research · 2018
  not yet assessed
• <i>IL21R</i> expressing CD14 ⁺ CD16 ⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts ↗

  Haematologica · 2017 · PMID 28057743
  not yet assessed
• A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes ↗

  Blood · 2017
  not yet assessed
• Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target ↗

  Blood · 2016 · PMID 27268090
  not yet assessed
• miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma ↗

  Oncotarget · 2016 · PMID 26871295
  not yet assessed
• Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma⚑

  Oncotarget · 2016 · PMID 26895470
  L1 36/100 ⚑
• lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome ↗

  Blood Cancer Journal · 2016 · PMID 27611921
  not yet assessed
• Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo ↗

  Leukemia · 2016 · PMID 27311934
  not yet assessed
• In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma ↗

  Genes · 2016 · PMID 27916857
  not yet assessed
• Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components ↗

  Blood · 2016
  not yet assessed
• DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY

  Haematologica · 2016
  not yet assessed
• Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs

  2016
  not yet assessed
• Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts ↗

  Blood · 2015 · PMID 26463425
  not yet assessed
• Molecular spectrum of <i>BRAF, NRAS</i> and <i>KRAS</i> gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation ↗

  Oncotarget · 2015 · PMID 26090869
  not yet assessed
• A compendium of <i>DIS3</i> mutations and associated transcriptional signatures in plasma cell dyscrasias ↗

  Oncotarget · 2015 · PMID 26305418
  not yet assessed
• Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma ↗

  Oncotarget · 2015 · PMID 26056083
  not yet assessed
• Disentangling the microRNA regulatory<i>milieu</i>in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients ↗

  Oncotarget · 2015 · PMID 26496024
  not yet assessed
• Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine ↗

  International Journal of Molecular Sciences · 2015 · PMID 26263974
  not yet assessed
• Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2015 · PMID 25860243
  not yet assessed
• Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia ↗

  PLoS ONE · 2015 · PMID 25786252
  not yet assessed
• Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers ↗

  Nature Medicine · 2014 · PMID 24813251
  not yet assessed
• microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters ↗

  Clinical Cancer Research · 2014 · PMID 24916701
  not yet assessed
• High‐throughput sequencing for the identification of <i><scp>NOTCH</scp>1</i> mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications ↗

  British Journal of Haematology · 2014 · PMID 24579978
  not yet assessed
• Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia ↗

  Genes Chromosomes and Cancer · 2014 · PMID 24706380
  not yet assessed
• Next-Generation Sequencing in Multiple Myeloma: Insights into the Molecular Heterogeneity of the Disease ↗

  International Journal of Hematologic Oncology · 2014
  not yet assessed
• Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma ↗

  Blood · 2014
  not yet assessed
• Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14+ Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis ↗

  Blood · 2014
  not yet assessed
• IMPROVED RISK STRATIFICATION IN MULTIPLE MYELOMA USING A MICRORNA-BASED CLASSIFIER ↗

  Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · 2014
  not yet assessed
• Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts ↗

  Blood · 2014
  not yet assessed
• Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction ↗

  Leukemia · 2013 · PMID 23344526
  not yet assessed
• Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia ↗

  Clinical Cancer Research · 2013 · PMID 23613318
  not yet assessed
• Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features ↗

  Clinical Cancer Research · 2013 · PMID 24036852
  not yet assessed
• Improved risk stratification in myeloma using a micro<scp>RNA</scp>‐based classifier ↗

  British Journal of Haematology · 2013 · PMID 23718138
  not yet assessed
• Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia ↗

  Leukemia · 2013 · PMID 23958922
  not yet assessed
• Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia ↗

  BMC Medical Genomics · 2013 · PMID 24004562
  not yet assessed
• Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome ↗

  Clinical Cancer Research · 2013 · PMID 23599371
  not yet assessed
• Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing ↗

  Expert Opinion on Biological Therapy · 2013 · PMID 23614397
  not yet assessed
• Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia ↗

  Genes Chromosomes and Cancer · 2013 · PMID 24347044
  not yet assessed
• High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications ↗

  Blood · 2013
  not yet assessed
• Storti HOXB7 MM 2011 LEUKEMIA

  2013
  not yet assessed
• Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation ↗

  Leukemia · 2012 · PMID 22289923
  not yet assessed
• Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma ↗

  Blood · 2012 · PMID 22740451
  not yet assessed
• Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells ↗

  Leukemia · 2012 · PMID 22781592
  not yet assessed
• The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma ↗

  Blood Cancer Journal · 2012 · PMID 23178508
  not yet assessed
• Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules ↗

  Experimental Hematology · 2012 · PMID 23178378
  not yet assessed
• Genome‐wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles ↗

  American Journal of Hematology · 2012 · PMID 23044976
  not yet assessed
• MicroRNAs in the Pathobiology of Multiple Myeloma ↗

  Current Cancer Drug Targets · 2012 · PMID 22671930
  not yet assessed
• Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors ↗

  Clinical Cancer Research · 2012 · PMID 22322667
  not yet assessed
• B‐cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia ↗

  American Journal of Hematology · 2012 · PMID 23115077
  not yet assessed
• Chromosome 2p gain in monoclonal B‐cell lymphocytosis and in early stage chronic lymphocytic leukemia ↗

  American Journal of Hematology · 2012 · PMID 23044996
  not yet assessed
• Improved Risk Stratification in Myeloma Using Microrna-Based Classifier ↗

  Blood · 2012
  not yet assessed
• The Expression Pattern of Small Nucleolar and Small Cajal Body-Specific RNAs Characterizes Distinct Molecular Subtypes of Multiple Myeloma ↗

  Blood · 2012
  not yet assessed
• Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia ↗

  Blood · 2012
  not yet assessed
• Genome-wide approach identify recurrent 8p21.2 loss in more aggressive form of primary plasma-cell leukemia

  2012
  not yet assessed
• The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease ↗

  2012
  not yet assessed
• Abstract 4575: Three-gene diagnostic classifier for ALK negative ALCL ↗

  Cancer Research · 2012
  not yet assessed
• Hypoxia-inducible factor (HIF)-1 alpha as a therapeutical target in myeloma induced angiogenesis and bone destruction in vitro and in vivo

  DSpaceUnipr (University of Parma) · 2012
  not yet assessed
• Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo. ↗

  Blood · 2012
  not yet assessed
• Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance ↗

  Blood · 2012
  not yet assessed
• B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia ↗

  Blood · 2012
  not yet assessed
• Patterns of global DNA methylation identify early stage (Binet A) CLL patients with higher risk of disease progression

  2012
  not yet assessed
• Immune Thrombocytopenia in Patients with Chronic LymphocyticLeukemiaIsAssociatedwithStereotypedB-cell Receptors

  2012
  not yet assessed
• The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma ↗

  Clinical Cancer Research · 2011 · PMID 21890453
  not yet assessed
• Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia ↗

  Epigenetics · 2011 · PMID 20930513
  not yet assessed
• Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma ↗

  PLoS ONE · 2011 · PMID 21731718
  not yet assessed
• Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression ↗

  PLoS ONE · 2011 · PMID 21909367
  not yet assessed
• Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia ↗

  PLoS ONE · 2011 · PMID 21897877
  not yet assessed
• Overexpression of <i>HOXB7</i> and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations ↗

  American Journal of Hematology · 2011 · PMID 21953534
  not yet assessed
• The Activation of Wnt5a-Mediated Non Canonical Wnt Signaling in Human Bone Marrow Osteoprogenitor Cells Increases Osteoblastogenesis and Counterbalances the Inhibitory Effect of Myeloma Cells on Ror2/FZD5 Expression, ↗

  Blood · 2011
  not yet assessed
• Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis ↗

  Blood · 2011
  not yet assessed
• The investigation of genomic profiles in plasma cell leukemias by means of an integrative microarray approach

  Haematologica · 2011
  not yet assessed
• Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors ↗

  Blood · 2011
  not yet assessed
• 1.2 Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of CLL ↗

  Clinical Lymphoma Myeloma & Leukemia · 2011
  not yet assessed
• 3.20 Stereotyped B-Cell Receptor is Associated with Immune Thrombocytopenia in CLL ↗

  Clinical Lymphoma Myeloma & Leukemia · 2011
  not yet assessed
• Abstract 1229: Prognostic significance of telomere length in B-chronic lymphocytic leukemia patients in early stage disease ↗

  Cancer Research · 2011
  not yet assessed
• Identification of molecular classifiers and key signalling networks in T-cell lymphoproliferative disorders through gene expression profiling meta-analyses

  2011
  not yet assessed
• The reconstruction of transcriptional regulatory networks reveals critical genes which have implications for clinical outcome of multiple myeloma

  2011
  not yet assessed
• Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease, ↗

  Blood · 2011
  not yet assessed
• Genome-Wide Analysis of Primary Plasma-Cell Leukemia Identifies Recurrent Imbalances Associated with Transcriptional Profile Alterations ↗

  Blood · 2011
  not yet assessed
• Prognostic significance of telomere length in chronic lymphocytic leukemia patients in early stage disease

  2011
  not yet assessed
• Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms ↗

  Journal of Clinical Oncology · 2010 · PMID 20159827
  not yet assessed
• Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion ↗

  Clinical Cancer Research · 2010 · PMID 20947517
  not yet assessed
• HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients ↗

  Leukemia · 2010 · PMID 21183939
  not yet assessed
• Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients ↗

  Leukemia · 2010 · PMID 20485369
  not yet assessed
• The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and RANKL/OPG Ratio In Myeloma Microenvironment Targeting the Expression of Adhesion Molecules ↗

  Blood · 2010
  not yet assessed
• The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide ↗

  Experimental Hematology · 2010 · PMID 20977926
  not yet assessed
• In Vitro and In Vivo Evidences of Osteocyte Involvement In Myeloma-Induced Osteolysis ↗

  Blood · 2010
  not yet assessed
• Abstract 2161: Network-based inference of ALK oncogenic signaling in T-cell lymphoproliferative disorders ↗

  Cancer Research · 2010
  not yet assessed
• Abstract 181: Biological and clinical relevance of quantitative global methylation in repetitive DNA sequences in B-cell chronic lymphocytic leukemia ↗

  Cancer Research · 2010
  not yet assessed
• Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group ↗

  Blood · 2010
  not yet assessed
• Unveiling the pathogenetic role of Stat3 in human lymphoma

  2010
  not yet assessed
• Network-based inference of ALK oncogenic signaling in T-cell lymphoproliferative disorders

  2010
  not yet assessed
• Integrative Genomic Analysis of Primary Plasma Cell Leukemia Revealed Strong Gene and MicroRNA Dosage Effect ↗

  Blood · 2010
  not yet assessed
• Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma ↗

  Blood · 2009 · PMID 19846888
  not yet assessed
• A SNP microarray and FISH‐based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect ↗

  Genes Chromosomes and Cancer · 2009 · PMID 19396863
  not yet assessed
• Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease ↗

  Experimental Hematology · 2009 · PMID 19963035
  not yet assessed
• Integrative high‐resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles ↗

  Genes Chromosomes and Cancer · 2009 · PMID 19306352
  not yet assessed
• CRITICAL ANALYSIS OF TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATORY NETWORKS IN MULTIPLE MYELOMA ↗

  WORLD SCIENTIFIC eBooks · 2009 · PMID 19908392
  not yet assessed
• Identification of MicroRNA Expression Patterns and Definition of a MicroRNAs/mRNA Regulatory Network in Distinct Molecular Groups of Multiple Myeloma. ↗

  Blood · 2009
  not yet assessed
• HOXB7 Is Critically Involved in Multiple Myeloma-Induced Angiogenic Switch. ↗

  Blood · 2009
  not yet assessed
• Are the Myeloma Bone Microevironment Cells Tumoral or Not?. ↗

  Blood · 2009
  not yet assessed
• Reverse Engineering and Critical Analysis of Gene Regulatory Networks in Multiple Myeloma

  Padua Research Archive (University of Padova) · 2009
  not yet assessed
• Molecular anatomy of peripheral T cell lymphomas

  2009
  not yet assessed
• Gene expression profiling uncovers molecular classifiers for the recognition of Anaplastic Large Cell Lymphoma within Peripheral T-cell neoplasms

  2009
  not yet assessed
• Integrative high-resolution microarrays approach in B-cell chronic lymphocytic leukemia reveals the presence of molecularly distinct subgroups in patients with 13Q deletion

  2009
  not yet assessed
• High-resolution microarray characterization of the 13q14 deletion extent in B-cell chronic lymphocytic leukemia : correlation with copy number and expression levels of mir-15a/16 cluster

  2009
  not yet assessed
• Global microrna expression profiling in multiple myeloma identifies deregulated patterns associated with distinct molecular groups

  2009
  not yet assessed
• Integrative genomic approach based on SNP-array and gene expression profiling reveals the presence of molecularly distinct subgroups in early stage b-cell chronic lymphocytic leukemia

  2009
  not yet assessed
• An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma ↗

  BMC Medical Genomics · 2008 · PMID 18700954
  not yet assessed
• Molecular and transcriptional characterization of 17p loss in B‐cell chronic lymphocytic leukemia ↗

  Genes Chromosomes and Cancer · 2008 · PMID 18521849
  not yet assessed
• Identification of primary MAFB target genes in multiple myeloma ↗

  Experimental Hematology · 2008 · PMID 19013005
  not yet assessed
• HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis ↗

  Blood · 2008
  not yet assessed
• Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis ↗

  Leukemia Research · 2008 · PMID 18355918
  not yet assessed
• Integrative genomics based on microarrays analyses reveals a correlation between allelic imbalances and gene expression patterns in multiple myeloma

  Haematologica · 2008
  not yet assessed
• Genome-Wide DNA Copy Number Analysis by SNP Arrays of B-Cell Chronic Lymphocytic Leukemia: Correlation with Known Biological and Molecular Prognostic Markers. ↗

  Blood · 2008
  not yet assessed
• Integrative Genomic Approach Identifies Deregulated MicroRNAs in Human Myeloma Cell Lines. ↗

  Blood · 2008
  not yet assessed
• Bone Microenvironment Cells Show a Different Pattern of Gene Expression Profiling in Relationship with the Presence of Osteolytic Bone Lesions in Multiple Myeloma Patients ↗

  Blood · 2008
  not yet assessed
• The expression signature of Anaplastic Large Cell Lymphomas: from cell line to primary tumors

  2008
  not yet assessed
• Genomic and functional approaches as powerful tools to stratify human T-cell lymphoproliferative disorders and to identify relevant tumorigenic culprits

  2008
  not yet assessed
• MicroRNA genes associated with genomic alterations or gene expression modulation contribute to enhance genetic heterogeneity in Multiple Myeloma

  2008
  not yet assessed
• Integrative genomic approach of the molecular biology of multiple myeloma

  IRIS UNIMORE (University of Modena and Reggio Emilia) · 2008
  not yet assessed
• Integrative genomic analysis of trisomy 12 abnormality in B-cell chronic lymphocytic leukemia

  2008
  not yet assessed
• Analysis of CD44 expression in monoclonal gammopathies : correlation between gene expression level and flow cytometry findings

  2008
  not yet assessed
• Bone microenvironment cells reveals a different gene expression profyling in multiple myeloma patients in relation to the bone status

  2008
  not yet assessed
• Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma ↗

  British Journal of Haematology · 2007 · PMID 17367409
  not yet assessed
• Transcriptional features of multiple myeloma patients with chromosome 1q gain ↗

  Leukemia · 2007 · PMID 17315022
  not yet assessed
• Molecular and transcriptional characterization of the novel 17p11.2‐p12 amplicon in multiple myeloma ↗

  Genes Chromosomes and Cancer · 2007 · PMID 17823926
  not yet assessed
• Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma ↗

  Haematologica · 2007 · PMID 17229636
  not yet assessed
• Gene Expression Profiling of Isolated Mesenchymal and Osteoblastic Cells Exhibits a Different Pattern of Expression in Multiple Myeloma Patients as Compared to Healthy Subjects: Potential Relationship with the Presence of Bone Lesions. ↗

  Blood · 2007
  not yet assessed
• Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles. ↗

  Blood · 2007
  not yet assessed
• Effect of Dioxin (TCDD) on Gene Transcription of Human CD34+ Hematopoietic Cells. ↗

  Blood · 2007
  not yet assessed
• Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Chromosome Amplification in Multiple Myeloma. ↗

  Blood · 2007
  not yet assessed
• Transcriptional features of 1Q in multiple myeloma

  Haematologica · 2007
  not yet assessed
• Genome-wide analysis of DNA copy number changes in multiple myeloma using high-density SNP arrays

  2007
  not yet assessed
• Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes ↗

  Journal of Clinical Investigation · 2006 · PMID 17111047
  not yet assessed
• Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease ↗

  Genes Chromosomes and Cancer · 2006 · PMID 17171682
  not yet assessed
• The prevalence and clinical implications of c‐kit expression in plasma cell myeloma ↗

  Histopathology · 2006 · PMID 16623778
  not yet assessed
• Identification of Specific Transcriptional Patterns Associated with Hyperdiploidy in Multiple Myeloma. ↗

  Blood · 2006
  not yet assessed
• Relevance of <i>Ras</i> gene mutations in the context of the molecular heterogeneity of multiple myeloma ↗

  Hematological Oncology · 2006 · PMID 17036375
  not yet assessed
• DKK-1 and sFRP-3 Expression by Myeloma Cell and Bone Marrow Plasma Levels in Multiple Myeloma and MGUS Patients: Potential Relationship with Bone Status. ↗

  Blood · 2006
  not yet assessed
• Mesenchymal and Osteoblastic Cells Isolated from Multiple Myeloma Patients Reveal a Different Behavior, Phenotype and Gene Expression Profiling in Relationship with the Presence of Osteolytic Bone Lesions. ↗

  Blood · 2006
  not yet assessed
• Prevalence of ras gene mutations in the context of a molecular classification of multiple myeloma

  2006
  not yet assessed
• The candidate tumor suppressor ing4 regulate IL-8 production in human multiple myeloma cells and it is involved in their pro-angiogenic properties

  2006
  not yet assessed
• Anaplastic lymphoma kinase : meccanismi molecolari e trasformazione linfoide

  2006
  not yet assessed
• Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma ↗

  Oncogene · 2005 · PMID 15735737
  not yet assessed
• Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing <i>CCND1</i> and Negative for 14q32 Translocations ↗

  Journal of Clinical Oncology · 2005 · PMID 16129847
  not yet assessed
• Transcription repression activity is associated with the type I isoform of the <i>MMSET</i> gene involved in t(4;14) in multiple myeloma ↗

  British Journal of Haematology · 2005 · PMID 16197452
  not yet assessed
• Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations. ↗

  Blood · 2005
  not yet assessed
• Transcription repression activity is associated with the type I isoform of the MMSET gene involved in the t(4;14) in multiple myeloma

  Haematologica · 2005
  not yet assessed
• Molecular profiles associated with cyclins D dysregulation and IGH translocations in multiple myeloma

  2005
  not yet assessed
• Different Gene Expression Profiles of CD133+ Cells from Cord Blood and Mobilized Peripheral Blood. ↗

  Blood · 2005
  not yet assessed
• 11Q13 polisomy and absence of IGH translocations and chromosome 13Q14 deletion characterize a distinct subgroup of multiple myeloma patients expressing CCND

  2005
  not yet assessed
• Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses ↗

  Genes Chromosomes and Cancer · 2004 · PMID 15543617
  not yet assessed
• Characterization of Oncogene Dysregulation in Multiple Myeloma by Combined FISH and DNA Microarray Analyses. ↗

  Blood · 2004
  not yet assessed
• Gene Expression Profiling of Plasma Cell Dyscrasias: The Role of IGH Translocations in the Heterogeneity of Multiple Myeloma. ↗

  Blood · 2004
  not yet assessed
• Gene expression analysis of cord blood stem cells

  2004
  not yet assessed